Navigation Links
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Date:4/16/2012

possible."

The IB1001 BLA filing includes a comprehensive set of pharmacokinetics safety, and efficacy data from a Phase 3 clinical trial in people affected by hemophilia B.  A surgery substudy was also included.

John Taylor, Co-Founder and Chairman of Inspiration, stated, "With sons affected by hemophilia B, Inspiration co-founder Scott Martin and I are acutely aware of the impact of limited treatment options on families. We believe more choice can help us achieve our mission to broaden access to care—increasing the supply of products, driving healthy competition, and supporting prophylaxis, which is rapidly becoming the standard of care in hemophilia. We believe that the approval of IB1001 will be the first step in our journey to make broader access to care a reality for thousands of individuals with hemophilia."

About IB1001IB1001 is an intravenous rFIX product being developed for the treatment and prevention of bleeding in individuals with hemophilia B.  IB1001 has completed pivotal Phase 3 clinical studies that support the filling of the BLA, conducted at study sites in the U.S., Europe and India.

To date, IB1001 has been well tolerated by patients and pharmacokinetic (PK) analyses have demonstrated non-inferiority to the one approved rFIX product currently marketed for the treatment of hemophilia B.  Confirmatory PK studies reported at the 53rd Annual Meeting of the American Society of Hematology showed no evidence of development of inhibitors during treatment periods ranging from 4 to 18 months.

Results recently presented at the 5th Annual Congress of the European Association for Haemophilia and Allied Disorders demonstrated that IB1001 provided effective surgical hemostasis in study participants with hemophilia B undergoing major surgical procedures.

About Inspiration BiopharmaceuticalsInspiration Biopharmaceuticals is exclusively dedicated to developing treatments for hemophilia, with a
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
4. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
7. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
8. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
9. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
10. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
11. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... San Diego, CA, and Bellingham, WA (PRWEB) August ... nanoscience and optical engineering, visions for next-generation wearable ... Light 2015 among numerous highlights at this year’s ... in the San Diego, California, Convention Center. More ... suppliers last week attended conferences, courses, an exhibition, ...
(Date:8/26/2014)... and REHOVOT, Israel , August 26, ... 3D printing specialist, Replica 3DM, supports NHS hospitals with surgery ...   - Performing surgery on 3D ... times; improves patient recovery and provides an effective aid for ... Ltd. (Nasdaq: SSYS ), a global leader ...
(Date:8/26/2014)... CA (PRWEB) August 26, 2014 The ... USD 8,020.1 million by 2020, according to a new ... personalized medicine and theranostics, and the subsequent introduction of ... factors driving market growth over the next six years. ... chronic diseases such as cancer, coupled with disease triggering ...
(Date:8/26/2014)... Aug. 26, 2014  Guardant Health, a healthcare ... oncology diagnostic products, has been recognized today by ... Technology Pioneer . As an innovator in non-invasive, ... companies across a wide variety of industries and ... Guardant360 ® , Guardant Health,s first commercially ...
Breaking Biology Technology:Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the ... 28, 2010 , after the market closes. The press release will be followed ... open to the public via telephone and webcast. During the conference call, the ... , , ...
... EXTON, Pa. , July 21 ViroPharma Incorporated,s (Nasdaq: VPHM ... Wednesday, July 28, 2010 before the open of the U.S. financial markets. , ... The company will host a conference call and live ... the conference call, ViroPharma management will discuss the 2010 second quarter financial results and ...
... RESEARCH TRIANGLE PARK, N.C. , July 21 Chimerix, ... it has expanded its clinical management team with the appointment of ... and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.   ... In these ...
Cached Biology Technology:Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast 2ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3
(Date:8/27/2014)... in German . ... common inherited disease affecting the peripheral nervous system. Researchers ... Institute of Experimental Medicine and University Medical Centre Gttingen ... impaired in rats with the disease. These cells enwrap ... myelin, which facilitates the rapid transfer of electrical impulses. ...
(Date:8/27/2014)... willing to pay a premium for fruits, vegetables and ... the label claims is another matter. Now scientists studying ... to make sure farms are labelling their produce appropriately. ... Agricultural and Food Chemistry , could help prevent organic ... Food Safety Authority and the Wuerzburg University note that ...
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
Breaking Biology News(10 mins):Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... canary in the coal mine, penguins are sounding ... world,s oceans, and the culprit isn,t only climate ... Oil pollution, depletion of fisheries and rampant ... penguin species, along with Earth,s warming climate, are ...
... current standard practice of giving infants and children 100 ... deprivation may actually inflict additional harm, researchers at UT ... by oxygen deprivation, known as hypoxic-ischemic brain injury, is ... long-term neurological damage among infants and children. This can ...
... Twelve investigators have received grants totaling $5 million ... of food allergy, a significant public health concern. ... is funded by the National Institute of Allergy ... Institutes of Health, and two advocacy groups, the ...
Cached Biology News:Penguins setting off sirens over health of world's oceans 2Penguins setting off sirens over health of world's oceans 3Penguins setting off sirens over health of world's oceans 4Resuscitation technique after brain injury may do more harm than good 2NIAID announces grants to stimulate food allergy research 2NIAID announces grants to stimulate food allergy research 3
... a commonly used technique for studying protein ... electrophoresed on SDS-PAGE and transferred to a ... they are probed with specific antibodies. Unlike ... of Southern and Northern blots, it has ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
Biology Products: